ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Zeria Pharmaceutical Co., Ltd. ?
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 8.92% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 8.64% signifying low profitability per unit of shareholders funds
2
Positive results in Mar 26
- RAW MATERIAL COST(Y) Fallen by -1.68% (YoY)
- CASH AND EQV(HY) Highest at JPY 51,914.35 MM
- DEBT-EQUITY RATIO (HY) Lowest at 11.62 %
3
With ROCE of 9.33%, it has a fair valuation with a 1.10 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -1.97%, its profits have fallen by -8%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -1.97% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Zeria Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zeria Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zeria Pharmaceutical Co., Ltd.
-1.97%
-0.02
19.62%
Japan Nikkei 225
85.83%
3.09
27.80%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.92%
EBIT Growth (5y)
18.15%
EBIT to Interest (avg)
21.87
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.63
Tax Ratio
21.01%
Dividend Payout Ratio
20.85%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.96%
ROE (avg)
8.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.12
EV to EBIT
11.81
EV to EBITDA
6.97
EV to Capital Employed
1.10
EV to Sales
1.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.33%
ROE (Latest)
7.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -1.68% (YoY
CASH AND EQV(HY)
Highest at JPY 51,914.35 MM
DEBT-EQUITY RATIO
(HY)
Lowest at 11.62 %
DIVIDEND PER SHARE(HY)
Highest at JPY 3.11
NET SALES(Q)
Highest at JPY 25,082.06 MM
PRE-TAX PROFIT(Q)
At JPY 3,916.18 MM has Grown at 80.36%
NET PROFIT(Q)
At JPY 2,900.39 MM has Grown at 69.25%
-11What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.28 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.11 times
INTEREST(Q)
Highest at JPY 138.8 MM
Here's what is working for Zeria Pharmaceutical Co., Ltd.
Net Sales
Highest at JPY 25,082.06 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Pre-Tax Profit
At JPY 3,916.18 MM has Grown at 80.36%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 2,900.39 MM has Grown at 69.25%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
Cash and Eqv
Highest at JPY 51,914.35 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at 11.62 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Dividend per share
Highest at JPY 3.11
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (JPY)
Raw Material Cost
Fallen by -1.68% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at JPY 1,960.52 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Zeria Pharmaceutical Co., Ltd.
Interest
At JPY 138.8 MM has Grown at 12.95%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Interest
Highest at JPY 138.8 MM
in the last five periods and Increased by 12.95% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Inventory Turnover Ratio
Lowest at 1.28 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 3.11 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
